Search for Clinical Trial Results
Cell Transformation, Neoplastic - 25 Studies Found
Status | Study |
Active, not recruiting |
Study Name: Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer Condition:
|
Completed |
Study Name: Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation Condition: Leukemia Date: 2007-10-22 Interventions:
|
Active, not recruiting |
Study Name: A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients Condition: Chronic Myelogenous Leukemia Date: 2015-07-26 Interventions: Drug: Flumatinib mesylate tablet 600 mg qd Flumatinib mesylate tablet 600 mg qd in CML-AP or CML-BP pati |
Active, not recruiting |
Study Name: Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML Condition:
|
Recruiting |
Study Name: Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML Condition:
Date: 2012-09-11 Interventions: Drug: Nilotinib+AD induction • Post-remission consol |
Recruiting |
Study Name: An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357) Condition: Leukemia Date: 2011-12-21 Interventions:
|
Completed |
Study Name: Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial Condition: Chronic Myelogenous Leukemia Date: 2011-06-06 Interventions: Drug: nilotinib Other Name: AMN107 |
Terminated |
Study Name: Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia Condition:
|
Completed |
Study Name: A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Condition: Chronic Myeloid Leukemia Date: 2010-05-18 Interventions: Drug: Nilotinib |
Approved for marketing |
Study Name: Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Condition: Chronic Myeloid Leukemia Date: 2009-05-18 Interventions: Drug: Nilotinib |